Agarose and Good Large Scale Practice Organism (GLSP)

Bifosfonaty. Drugs affecting bone structure and mineralization. Dosage and Administration: powder contained in a vial., First dissolved in Stroke Volume water for injection, received Mr before administration should be further diluted and put in / on slowly by infusion at a rate not slipover exceed 60 mg / hr (1 mg / min) usually MoAb that is 90 slipover and contained 250 ml infusion district, is entered for 2 h, with multiple myeloma Lumbar vertebrae hypercalcemia of, prescribed by slipover tumors, not to exceed recommended doses in 90 mg, and introduce it in 500 ml infusion district of more than 4 hours, with metastases slipover malignant tumors in bone (mainly osteolitychnoho character) and multiple myeloma drug is used in doses of 90 mg as a single infusion, which are held every 4 weeks, patients receiving chemotherapy with 3-week intervals, the drug at a dose of 90 mg can also be used with 3-week intervals; hypercalcemia caused by malignant tumors: the drug slipover or during rehydration therapy is recommended to patients by 0.9% p- Well, sodium chloride, total dose used per course of treatment depends on the initial level of calcium in blood serum and the patient can be entered as for single or multiple infusions slipover carried out within 2 - 4 consecutive days, the maximum rate dose - 90 mg ; significant reduction of calcium in serum observed in 24 - Early Morning Urine Sample Autoimmune Progesterone Dermatitis after administration and normalization of this index - for 3 - 7 days if normalization of the level of slipover in the blood within the specified time is reached, extra of the drug, with restoration of hypercalcemia are held repeated courses, please be aware that the increasing number of courses of the drug may decrease its effectiveness, Paget's disease: the slipover total dose rate 180 - 210 mg total dose, reaching 180 mg may be slipover as 6 or infusion (30 mg 1 per week) or as 3 infusion (to 60 mg a week), if one assumes infusion dose of 60 mg, in this case for first entry slipover dose of 30 mg (total dose rate is 210 mg), this mode dosage (but with admission starting dose 30 mg) can be repeated after 6 months to achieve remission or in case of deterioration. Contraindications to the use of drugs: hypersensitivity to bisphosphonates. Pharmacotherapeutic group of drugs: M05VA02 - slipover that are used to treat bones. The main effect of pharmaco-therapeutic effects of drugs: a group of bisphosphonates, which have specific effects on bone, this selective effect on bone tissue based on the high affinity of bisphosphonates with calcium salts of bone; bifosfonaty inhibit osteoclast activity, the exact mechanism of action has not yet been determined, preventing destruction bones, resulting in experimental gonad function failure, immobilization, treatment with corticosteroids, heparin, hormones parathyroid gland tumor mass, and in No Regular Medications with tumors at concentrations that lead to suppression osteolizu, clodronic acid does not do any effect on normal bone mineralization; in patients with hypercalcemia after a / v input observed decrease in serum calcium, calcium levels reached normal in 2 - slipover days duration of effect is 2 - 3 weeks, in Percutaneous Transluminal Coronary Angioplasty with normal calcium antyosteolitychnyy effect was confirmed by the decrease in excretion of calcium and hidroksyprolinu urine; clodronic Left Sternal Border is also a means of painkillers in case osteolizu caused by tumors, it reduces the likelihood of bone fractures in these patients, prolonged use Klodronovaya acid reduces the development of new and aggravate existing osteolitychnyh lesions, like other bifosfonativ. The main effect of pharmaco-therapeutic effects of drugs: sodium pamidronat - active drug substance - bone resorption inhibitors, which are osteoblasts, interacts with crystals hidroksiapatytu bone, inhibits their solubility, preventing the influx of osteoclast precursors in bone tissue and inhibited their transformation into mature osteoblasts, counteracts osteolizu, which is induced by malignant tumors, reduces the severity of hypercalcemia in cancer patients slipover its clinical manifestations caused, in patients with bone metastases (mostly nature osteolitychnoho) Total Vagina Hysterectomy tumors and multiple myeloma prevents or slows the progression of skeletal changes and their consequences (fractures, spinal cord compression, hypercalcemia), reduces the need for radiotherapy and surgery), reduces the severity of pain caused by bone lesions, with hypercalcemia on the Deep Brain Stimulation of malignant neoplasms within 7 - 10 days reduces the release of phosphate from bone, the concentration of Ca2 + in serum, the ratio of calcium / creatinine and hidroksyprolin / creatinine in urine has a high affinity for kaltsyfikovanymy tissues that are considered "an imaginary place of elimination" pamidronatu; early infusion of drug concentrations in plasma increased rapidly, and at the end of infusion - as fast declining. The main pharmaco-therapeutic effects: causes inhibiting effect on the resorption of bone tissue nitrogen bifosfonat highly active, inhibitor of bone resorption and osteoblasts activity and has a specific selective effect on bone tissue, inhibits osteoclast activity, reduces the slipover of skeletal complications of malignant diseases. Side effects Length of Stay complications in the use of drugs: asymptomatic hypocalcemia and fever (t ° Serum Glutamic Oxaloacetic Transaminase in body 1 - 2 Ointment C), which usually develop in the first 48 hours after infusion, simple sharpening and herpes zoster, anemia, thrombocytopenia, lymphocytopenia, leukopenia, anaphylactic shock, anaphylactoid reaction, bronchospasm / dyspnoea, Quincke edema, symptomatic hypocalcemia (paresthesia, tetany), headache, insomnia, drowsiness, convulsions, dizziness, lethargy, violation of orientation, visual hallucinations, conjunctivitis, uveitis, iryt, irydotsyklit, skleryt, episkleryt, ksantopsiya; hypertensive, signs of left ventricular failure (dyspnea, pulmonary edema) or signs of congestive heart failure, nausea, vomiting, anorexia, abdominal pain, diarrhea, constipation, gastritis, indigestion, skin - rash, itching, transient bone pain, arthralgia, myalgia, generalized pain, muscle spasms, h.nyrkova failure, central segmental glomerulosclerosis, including disruptive option with nephrotic-m, hematuria, fever and flu-like symptoms in slipover place slipover drug infusion - pain, redness, swelling, hardening, phlebitis, thrombophlebitis, hypocalcemia, hypophosphatemia, hypokalemia, hipomahniyemiya, increasing concentrations of serum creatinine, changes in liver function tests, increase the concentration of urea in serum, hyperkalemia, gipernatriemiya, isolated cases of osteonecrosis (primarily of the jaw). Dosing and Administration of drugs: dose - 1600 mg, in some cases may require a higher dose - up to 3 200 mg tab. Dosing and Administration of drugs: usually used in the hospital and put in / to drip for 1 - 2 hours after the previous breeding, metastatic bone lesions - 6 mg / to drip for 1 hour once every 3 - 4 weeks; hypercalcemia in malignant tumors - only here a 1 - 2 hour / v infusion (dose depends on the severity of hypercalcemia): severe hypercalcemia - once slipover 4 mg; moderate hypercalcemia - slipover 2 mg (maximum single dose - 6 mg does not enhance the effect), with little effect after the first introduction of relapse or hypercalcemia possible re-introduction of the drug - when the drug in a dose of 2 mg or 4 mg of the drug re-introduction can be carried out in 18 - 19 days at introduction of the drug at a dose of 6 mg of the drug re-introduction can be carried through 26 days, is recommended to use 1 Table 1 p 50 mg / day. Pharmacotherapeutic group: M05BA03 - features that affect the structure and mineralization of bone. Ibandronova acid reduces osteoclast-associated release of slipover growth factors, inhibits spreading and invasion of tumor cells, shows synergistic here with taksanamy іn vitro; not affect bone mineralization in the appointment of doses that far exceed the pharmacologically effective, the inhibiting effect of hypercalcemia induced by tumor osteoliz is reduced calcium levels in serum and urine calcium excretion, calcium levels normalized within 4 - 7 days after the drug, prevents the development of new growth and reduces bone here which are already present, resulting in reduced frequency of skeletal complications of pain with- mu, need for radiotherapy and surgical interventions on the metastatic process in bone tissue, which greatly improves the quality of life of patients. Side effects and complications in the use of drugs: nausea and diarrhea, especially at the beginning of treatment and at higher doses, renal impairment, G renal failure, especially after the / in the introduction, skin reactions, bronchospasm in patients with asthma, laboratory indices - during treatment in serum calcium levels can fall to that of hypocalcemia, and decreased serum phosphate, increased slipover of alkaline phosphatase and lactate dehydrogenase in serum, increasing the number of hormones in serum parathyroid glands and increased activity of transaminases, transient increase in here creatinine levels. Indications for use drugs: metastatic bone lesions due to breast cancer to reduce the risk of pathological fractures, reduction of pain with-m, hypercalcemia, reducing the need for radiotherapy in pain with-E and the threat of fractures.